Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $0.41 USD
Change Today +0.0189 / 4.83%
Volume 138.5K
ENZN On Other Exchanges
As of 2:11 PM 02/11/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

20 Kingsbridge Road

Piscataway, NJ 08854

United States

Phone: 732-980-4500


Enzon Pharmaceuticals, Inc. engages in licensing drug products. The company receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, including PegIntron, Sylatron, Macugen, and CIMZIA. The primary source of the company’s royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. (Merck). PegIntron is a PEG-enhanced version of Merck’s alpha interferon product, INTRON A, which is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Merck holds an exclusive worldwide license to PegIntron. The company is entitled to receive royalties on Merck’s worldwide sales of PegIntron until certain expiration dates set forth in the license agreement which are expected to occur in 2016 in the U.S., 2018 in Europe and 2019 in Japan. Merck is responsible for all manufacturing, marketing, and development activities for PegIntron. The company designed PegIntron to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. In 2011, the United States Food and Drug Administration approved peginterferon alfa-2b (Sylatron) to treat melanoma with nodal involvement after surgical resection. The company has out-licensed its proprietary PEGylation and single-chain antibody technologies on its own and through agreements with Nektar Therapeutics, Inc. and Micromet AG. The company is party to a license and collaboration agreement with Santaris Pharma A/S pursuant to which the company held exclusive rights worldwide, other than in Europe, to develop and commercialize RNA antagonists directed against the HIF-1 alpha, and androgen receptor targets, as well as RNA antagonists directed against two additional gene targets selected by the company, such as HER3 and Beta-catenin. Peginterferon alfa 2b was approved for melanoma in 2011 under the brand name Sylatron. The company has a collaboration agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun) pursuant to which the company licensed to Hisun exclusive development and commercialization rights for PEG-SN38 in China. Under the terms of this agreement, the company retained rights for PEG-SN38 outside of China. Competition PegIntron, marketed by Merck, competes directly with Hoffmann-La Roche’s PEGASYS. History Enzon Pharmaceuticals, Inc. was founded in 1981.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $0.41 USD +0.0189

ENZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $15.76 USD +0.29
Nektar Therapeutics $11.37 USD +0.195
Onxeo SA €2.59 EUR -0.12
Regulus Therapeutics Inc $5.75 USD +0.07
Veloxis Pharmaceuticals A/S kr1.69 DKK -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation ENZN Industry Range
Price/Earnings 1.3x
Price/Sales 0.9x
Price/Book 1.1x
Price/Cash Flow 1.3x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ENZON PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at